Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'

We read with great interest the results of the recently published article titled 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'. This article provides information on reinduction with rituximab in a large cohort of relapsing AAV. This paper as the authors state reports only on the induction phase of the RITAZAREM¹ trial, prior to randomisation. The results of the randomised controlled trial (RCT) were discussed elsewhere.²

Ninety per cent of the enrolled subjects achieved remission with four weekly doses of rituximab (RTX). Majority (63%) had severe disease at baseline and surprisingly most of them (71%) received the lower regime of glucocorticoids starting at 0.5 mg/kg and tapered. These results provide evidence of short-term efficacy of RTX and help break inhibitions of using a low dose glucocorticoid regimen in severe relapsing AAV with rituximab as a reinduction agent.

The RAVE³ trial had a subgroup of severe relapses in which the remission rate was 67% and 42% in the RTX and cyclophosphamide groups, respectively. Remission was assessed at 6 months and was defined as Birmingham Vasculitis Activity Score/Wegener granulomatosis (BVAS/WG) of zero and complete glucocorticoid withdrawal. In this study, remission was defined as BVAS/WG of ≤ 1 and with prednisone dose of ≤ 10 mg/day by 4 months. Renal and pulmonary involvement was less frequent compared with the RAVE³ cohort (47% vs 66% and 37% vs 52%, respectively). Hence, the remission rates across the two studies are not directly comparable. The number of patients who received intravenous methyl prednisolone and plasma exchange in this study is also not mentioned and could act as confounders raising caution about interpreting the results.

The authors concluded that response to RTX in relapsing AAV was not influenced by age, ANCA type at enrolment, glucocorticoid induction regimen, presence of ear, nose and throat or renal involvement. However, they hinted that non-severe disease (with an OR of 2.93 and a wide CI) could predict response. The lack of a comparator arm in the induction phase and the extremely small number of non-responders caution us against generalising the results of efficacy of RTX in relapsing AAV.

The lower glucocorticoid (GC) subgroup had only 2/3 of total GC exposure. Contrary to expectations, the total number of serious and non-serious infections in the lower GC group outnumbered the group with the higher GC exposure (5.2% and 35.1% vs 0 and 22.2%, respectively). This is unexplained and

in contrast to report from the PEXIVAS⁴ study where serious infections were significantly lower in the reduced dose group.

We would also like to bring to attention that certain serious adverse events listed, namely vasculitis, laryngeal stenosis, DVT and pulmonary embolism were in all likelihood manifestations of the primary disease and could actually be reinterpreted as failure of RTX.

Akshay Parikh , **Phani Kumar Devarasetti**, **Liza Rajasekhara**

Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

Correspondence to Dr Liza Rajasekhara, Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad 500082, Telangana, India; lizarajasekhara@gmail.com

Contributors Each of the three authors have contributed equally to all aspects of authorship credit.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Parikh A, Devarasetti PK, Rajasekhara L. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-219312

Received 15 October 2020

Accepted 17 October 2020

► <https://doi.org/10.1136/annrheumdis-2020-219329>

Ann Rheum Dis 2021;0:1. doi:10.1136/annrheumdis-2020-219312

ORCID iD

Akshay Parikh <http://orcid.org/0000-0002-0060-4555>

REFERENCES

- Smith RM, Jones RB, Specks U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. *Ann Rheum Dis* 2020;79:1243–9.
- Smith R, Jayne D, Merkel P. A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease [abstract]. *Arthritis Rheumatol* 2019;71.
- Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221–32.
- Walsh M, Merkel PA, Peh C-A, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med* 2020;382:622–31.